Entrada Therapeutics (TRDA) Operating Margin (2023 - 2025)
Historic Operating Margin for Entrada Therapeutics (TRDA) over the last 3 years, with Q3 2025 value amounting to 2915.18%.
- Entrada Therapeutics' Operating Margin fell 28045100.0% to 2915.18% in Q3 2025 from the same period last year, while for Sep 2025 it was 197.59%, marking a year-over-year decrease of 2244400.0%. This contributed to the annual value of 22.3% for FY2024, which is 247500.0% up from last year.
- As of Q3 2025, Entrada Therapeutics' Operating Margin stood at 2915.18%, which was down 28045100.0% from 2402.51% recorded in Q2 2025.
- Over the past 5 years, Entrada Therapeutics' Operating Margin peaked at 56.42% during Q2 2024, and registered a low of 2915.18% during Q3 2025.
- Over the past 3 years, Entrada Therapeutics' median Operating Margin value was 22.88% (recorded in 2023), while the average stood at 502.43%.
- In the last 5 years, Entrada Therapeutics' Operating Margin surged by 1461200bps in 2024 and then plummeted by -28045100bps in 2025.
- Over the past 3 years, Entrada Therapeutics' Operating Margin (Quarter) stood at 11.72% in 2023, then crashed by -234bps to 15.69% in 2024, then tumbled by -18482bps to 2915.18% in 2025.
- Its Operating Margin was 2915.18% in Q3 2025, compared to 2402.51% in Q2 2025 and 105.99% in Q1 2025.